↓ Skip to main content

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based…

Overview of attention for article published in Frontiers in oncology, October 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
3 X users

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
Published in
Frontiers in oncology, October 2023
DOI 10.3389/fonc.2023.1209110
Pubmed ID
Authors

Ga-Young Song, Je-Jung Lee, Joon Ho Moon, Dajung Kim, Min Kyoung Kim, Hyo Jung Kim, Yeung-Chul Mun, Won-Sik Lee, Young Rok, Jae Hoon Lee, Sung-Hoon Jung, Jin Seok Kim

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 1 100%

Demographic breakdown

Readers by professional status Count As %
Other 1 100%
Readers by discipline Count As %
Medicine and Dentistry 1 100%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2023.
All research outputs
#16,608,224
of 26,180,352 outputs
Outputs from Frontiers in oncology
#5,857
of 22,924 outputs
Outputs of similar age
#177,026
of 369,981 outputs
Outputs of similar age from Frontiers in oncology
#143
of 912 outputs
Altmetric has tracked 26,180,352 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,924 research outputs from this source. They receive a mean Attention Score of 3.1. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 369,981 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 912 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.